showed that 5 patients achieved a partial response, 2 patients achieved a partial response unconfirmed by CT scan, and 14 patients achieved stable disease, for an overall major response rate of 20% and a disease-control rate of 60%. The most serious adverse reaction was Grade 3-4 neutropenia, which occurred in 57% of patients.
Quelle: Finanznachrichten
Das hört sich doch super an oder hab ich es falsch interpretiert, da geht heute die Lutzi ab...kein Handelsaufforderung |